

1632



HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

FORM PTO-1083

Attorney Docket No. 05882.0003.PCUS00

In re application of R. EHRHARDT

Appl. No. 09/857,823

Filed: June 7, 2001

Confirmation No.: 2366

For: **ANIMAL MODEL FOR PSORIASIS FOR THE PREVENTION AND TREATMENT OF
PSORIASIS IN HUMANS**

COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents for the above-identified application.


1. PTO Form 1083 (1 pg.);
2. Response to Restriction Requirement (5 pgs.);
3. Marked-Up Version to Show Changes Made to Specification (1 pgs.);
4. Marked-Up Version to Show Changes Made to Claims (1 pg.), and
5. Return Receipt Postcard.

xx The U.S. Patent and Trademark Office is hereby authorized to charge payment any fee deficiency or credit any overpayment to Deposit Account No. 08-3038 referencing docket number 05882.0003.PCUS00. A duplicate copy of this sheet is attached.

Date: August 30, 2002

Albert P. Halluin (Reg. No. 25,227)

Viola T. Kung (Reg. No. 41,131)



EXPRESS MAIL NO.: EL615211722US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2002

TECH CENTER 1600/2900

In re application of:
R. R. R. HARDT, *et. al.*

Appl. No.: 09/857,823

Filed: June 7, 2001

For: **ANIMAL MODEL FOR
PSORIASIS FOR THE
PREVENTION AND
TREATMENT OF PSORIASIS
IN HUMANS**

Art Unit: 1632

Examiner: Chen, Liping

Atty. Docket: 05882.0003.PCUS00

Confirmation No.: 2366

Response to Restriction Requirement

Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Office Action dated **July 31, 2002**, and is submitted on or before the extended due date of **August 31, 2002**. The Examiner is requested to enter the amendment prior to examination of the application.

THE AMENDMENTS

In the Title

Replace the paragraph beginning at page 1, line 1-2 with the following paragraph:

--METHOD OF TREATING PSORIASIS--.

In the Claims

Cancel Claims 1-24 and 28-32.

25. (Amended) A method of treating a patient suffering from psoriasis comprising the step of administering to the patient an antibody that binds to an antigen selected from the group consisting of interferon gamma, interleukin 12, and alphaE integrin subunit.